Clinical Trial Detail

NCT ID NCT03051672
Title Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor negative breast cancer

Therapies

Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST